KRAS and non-small cell lung carcinoma: We then investigated the effect of KYA1797K on these NSCLC cell lines to find out if KYA1797K could overcome the resistance of KRAS mutated NSCLC to erlotinib and observed that KYA1797K successfully overcomes the resistance of erlotinib in KRAS mutant cell lines.